Beacon Investment Advisory Services Inc. Buys 10,449 Shares of Gilead Sciences, Inc. $GILD

Beacon Investment Advisory Services Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 111,531 shares of the biopharmaceutical company’s stock after purchasing an additional 10,449 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Gilead Sciences were worth $13,689,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of GILD. Ameriprise Financial Inc. boosted its stake in Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares during the period. Invesco Ltd. raised its stake in shares of Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Gilead Sciences by 164.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock worth $387,286,000 after acquiring an additional 2,169,266 shares during the last quarter. First Trust Advisors LP boosted its stake in shares of Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after purchasing an additional 1,874,508 shares during the period. Finally, Amundi boosted its stake in shares of Gilead Sciences by 18.2% during the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after purchasing an additional 1,614,355 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Wolfe Research increased their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research report on Thursday, February 12th. Bank of America set a $162.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Barclays began coverage on Gilead Sciences in a report on Friday, February 20th. They issued an “equal weight” rating and a $155.00 price target on the stock. BMO Capital Markets boosted their price objective on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. Finally, JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $157.62.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction dated Friday, January 23rd. The shares were sold at an average price of $135.00, for a total transaction of $15,611,400.00. Following the transaction, the chief executive officer owned 566,698 shares of the company’s stock, valued at approximately $76,504,230. This trade represents a 16.95% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the sale, the insider owned 120,288 shares of the company’s stock, valued at approximately $18,577,278.72. This represents a 18.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 299,280 shares of company stock worth $42,820,550. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $134.25 on Monday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company has a market capitalization of $166.63 billion, a PE ratio of 19.83, a P/E/G ratio of 1.76 and a beta of 0.36. The company has a 50 day moving average price of $144.09 and a 200-day moving average price of $128.76. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be paid a dividend of $0.82 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s payout ratio is 48.45%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Ouro Medicines for up to about $2.18B to expand its inflammation/immunology franchise, strengthening longer‑term growth optionality beyond established HIV and antiviral products. Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
• Positive Sentiment: Gilead has been adding immunology and CAR‑T assets to diversify its pipeline and bolster oncology exposure — a strategic shift that could lift medium/long‑term revenue growth if integration and clinical readouts succeed. Can Gilead’s Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
• Positive Sentiment: Gilead recently reported an earningsbeat and set FY‑2026 EPS guidance in the $8.45–$8.85 range, signaling stable profitability and management confidence; consensus still trails that guidance, which supports valuation. Gilead Sciences Trading / Company Report
• Positive Sentiment: Erste Group nudged up its FY‑2026 EPS forecast for Gilead, a modest analyst raise that reinforces hopes for better-than-consensus earnings next year.
• Neutral Sentiment: Analyst consensus (average brokerage recommendation) sits at a Buy — helpful context but potentially already reflected in the share price; take analyst ratings as background, not a catalyst. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Zacks highlights Gilead as a value‑oriented pick under its style scores, which may attract income/value investors but is not an immediate price driver. Here’s Why Gilead Sciences (GILD) is a Strong Value Stock
• Neutral Sentiment: Industry event notices (e.g., SK pharmteco symposium) are peripheral to Gilead’s near‑term stock movement and unlikely to be material. SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium
• Negative Sentiment: Market skepticism: analyst optimism and “Buy” consensus could be priced in, and investors may be trimming positions after recent gains (Gilead has traded near a 52‑week high in the past year), leading to downward pressure. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Deal risk and near‑term cost: the ~ $2.2B acquisition and other purchases increase upfront cash outlays and execution risk (integration, trial outcomes), which can weigh on the stock until benefits are demonstrated.
• Negative Sentiment: Technical/flow factors: trading volume is below the stock’s average and the price is below the 50‑day moving average, consistent with the current down move and limited buying momentum.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.